• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Broussard Bruce D was granted 3,800 units of American Depositary Shares, increasing direct ownership by 478% to 4,595 units (SEC Form 4) (withholding obligation)

    7/6/26 6:12:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BROUSSARD BRUCE D

    (Last)(First)(Middle)
    C/O HP INC.
    1501 PAGE MILL ROAD

    (Street)
    PALO ALTO CALIFORNIA 94304

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    07/01/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    American Depositary Shares07/01/2026A(1)3,800A$04,595D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Tax Obligation Award(2)07/01/2026A1,31906/01/202906/01/2029Ordinary Shares1,319$01,319D
    Explanation of Responses:
    1. Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
    2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
    Remarks:
    /s/ Samuel Ntonme, by power of attorney, for Bruce D Broussard07/06/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $TAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/8/2026Mkt Perform → Outperform
    Bernstein
    1/13/2026Overweight
    Morgan Stanley
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gillis Steven was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) to satisfy withholding obligation

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:29:03 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Maraganore John was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (for withholding tax)

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:28:41 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Reed Kimberly A. was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (tax withholding)

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    7/6/26 6:28:22 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

    On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda ((TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent ora

    7/16/26 6:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

    Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased Initiative Takeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation Network Collaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients Takeda (NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today a

    7/12/26 7:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

    Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors   In the final step of its 18-month CEO transition, Takeda ((4502, NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusi

    6/24/26 3:05:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    SEC Filings

    View All

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/9/26 6:00:29 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    7/8/26 6:02:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    6/29/26 6:01:15 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Takeda Pharma upgraded by Bernstein

    Bernstein upgraded Takeda Pharma from Mkt Perform to Outperform

    4/8/26 9:38:13 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Takeda Pharma

    Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight

    1/13/26 8:31:07 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Pharma upgraded by Morgan Stanley

    Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

    4/2/25 8:46:19 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Financials

    Live finance-specific insights

    View All

    Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

    FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration   Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch

    5/13/26 2:38:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

    About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven

    3/28/26 3:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

    Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment   Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The comp

    1/29/26 1:37:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/6/24 9:36:34 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/5/24 6:24:58 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/7/23 2:10:49 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

    Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors   In the final step of its 18-month CEO transition, Takeda ((4502, NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusi

    6/24/26 3:05:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations